Low access to a highly effective therapy: a challenge for international tuberculosis control
- PMID: 12131999
- PMCID: PMC2567525
Low access to a highly effective therapy: a challenge for international tuberculosis control
Abstract
Objective: To determine the scale of the tuberculosis (TB) problem facing the international Stop TB Partnership by measuring the gap between present rates of case detection and treatment success, and the global targets (70% and 85%, respectively) to be reached by 2005 under the WHO DOTS strategy.
Methods: We analysed case notifications submitted annually to WHO from up to 202 (of 210) countries and territories between 1980 and 2000, and the results of treatment for patients registered between 1994 and 1999.
Findings: Many of the 148 national DOTS programmes in existence by the end of 2000 have shown that they can achieve high treatment success rates, close to or exceeding the target of 85%. However, we estimate that only 27% of all the new smear-positive cases that arose in 2000 were notified under DOTS, and only 19% were successfully treated. The increment in case-finding has been steady at about 133 000 additional smear-positive cases in each year since 1994. In the interval 1999- 2000, more than half of the extra cases notified under DOTS were in Ethiopia, India, Myanmar, the Philippines, and South Africa.
Conclusion: With the current rate of progress in DOTS expansion, the target of 70% case detection will not be reached until 2013. To reach this target by 2005, DOTS programmes must find an additional 333 000 cases each year. The challenge now is to show that DOTS expansion in the major endemic countries can significantly accelerate case finding while maintaining high cure rates.
Similar articles
-
Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project.Int J Tuberc Lung Dis. 1999 Apr;3(4):310-20. Int J Tuberc Lung Dis. 1999. PMID: 10206501
-
Ten-year experiences of the tuberculosis control programme in the southern region of Ethiopia.Int J Tuberc Lung Dis. 2006 Oct;10(10):1166-71. Int J Tuberc Lung Dis. 2006. PMID: 17044212
-
DOTS expansion: will we reach the 2005 targets?Int J Tuberc Lung Dis. 2004 Jan;8(1):139-46. Int J Tuberc Lung Dis. 2004. PMID: 14974757 Review.
-
Revised national TB control programme in India.Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):271-6. doi: 10.1016/j.tube.2005.08.003. Epub 2005 Oct 25. Tuberculosis (Edinb). 2005. PMID: 16253562
-
[How to cope with the global tuberculosis burden--experiences and perspectives for Japan's international cooperation].Kekkaku. 2005 Feb;80(2):89-94. Kekkaku. 2005. PMID: 15920981 Review. Japanese.
Cited by
-
Anti-tubercular activity evaluation of natural compounds by targeting Mycobacterium tuberculosis resuscitation promoting factor B inhibition: An in silico study.Mol Divers. 2024 Jun;28(3):1057-1072. doi: 10.1007/s11030-023-10632-8. Epub 2023 Mar 24. Mol Divers. 2024. PMID: 36964456
-
Expanding tuberculosis case detection by screening household contacts.Public Health Rep. 2005 May-Jun;120(3):271-7. doi: 10.1177/003335490512000309. Public Health Rep. 2005. PMID: 16134567 Free PMC article.
-
Impact of smoking on sputum culture conversion and pulmonary tuberculosis treatment outcomes in Brazil: a retrospective cohort study.J Bras Pneumol. 2018 Apr;44(2):99-105. doi: 10.1590/s1806-37562017000000161. J Bras Pneumol. 2018. PMID: 29791542 Free PMC article.
-
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.Lancet. 2009 Apr 4;373(9670):1183-9. doi: 10.1016/S0140-6736(09)60333-0. Lancet. 2009. PMID: 19345831 Free PMC article. Clinical Trial.
-
Expression, purification and characterization of Mycobacterium tuberculosis RpfE protein.J Biomed Res. 2012 Jan;26(1):17-23. doi: 10.1016/S1674-8301(12)60003-7. J Biomed Res. 2012. PMID: 23554726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous